IDiyas

For the Inventor, By the Inventor

San Francisco, CA, United States of America

Sillajen Biotherapeutics, Inc.


USPTO Granted Patents = 12



Trademarks = 2

Forward Citations = 60

Loading Chart...
Loading Chart...

17 inventors (with patents filed for the assignee):

goldMedal David H Kirn (12 out of 19 patents)

silverMedal John Cameron Bell (5 out of 30 patents)

bronzeMedal Caroline Breitbach (3 out of 4 patents)

4.  Anne Moon (2 out of 2 patents)

5.  Tae-Ho Hwang (2 out of 2 patents)

6.  Yu Kyoung Lee (2 out of 2 patents)

7.  Mi-kyung Kim (2 out of 2 patents)

8.  Steve H Thorne (1 out of 2 patents)


12 patents:

1. 10767166 - Methods and compositions for production of vaccina virus (2020-09-08),
2. 10434169 - Generation of antibodies to tumor antigens and generation of tumor specific complement dependent cytotoxicity by administration of oncolytic vaccinia virus (2019-10-08),
3. 10202581 - Methods and compositions for production of vaccinia virus (2019-02-12),
4. 9919062 - Oncolytic vaccinia virus cancer therapy (2018-03-20),
5. 9919047 - Generation of antibodies to tumor antigens and generation of tumor specific complement dependent cytotoxicity by administration of oncolytic vaccinia virus (2018-03-20),
6. 9827278 - Systemic treatment of metastatic and/or systemically-disseminated cancers using GM-CSF-expressing poxviruses (2017-11-28),
7. 9719105 - Methods and compositions for production of vaccinia virus (2017-08-01),
8. 9226977 - Oncolytic vaccinia virus cancer therapy (2016-01-05),
9. 9180151 - Oncolytic vaccinia virus combination cancer therapy (2015-11-10),
10. 9180149 - Systemic treatment of metastatic and/or systemically-disseminated cancers using GM-CSF-expressing poxviruses (2015-11-10),
11. 8986674 - Methods and compositions concerning poxviruses and cancer (2015-03-24),
12. 8980246 - Oncolytic vaccinia virus cancer therapy (2015-03-17),
SillaJen BioTherapeutics, Inc. is a clinical-stage biotechnology company focused on the development and commercialization of novel cancer immunotherapies. The company’s lead product candidate is Pexa-Vec, an oncolytic immunotherapy designed to induce tumor-specific immune responses and selectively target and destroy cancer cells. SillaJen is dedicated to providing innovative and effective treatments for patients with unmet medical needs in the field of oncology.
This text is generated by artificial intelligence and may not be accurate.

logo

Company Badge

USPTO Data Jan 1 1976 - Dec 2 2025

12 Patents

#370 in San Francisco, CA

#5,870 in California

#24,764 in US

#46,630 in the World

...
San Francisco, CA, United States of America

Sillajen Biotherapeutics, Inc.

Forward Citations = 60

17 inventors:

goldMedal David H Kirn (12 out of 19 patents)

silverMedal John Cameron Bell (5 out of 30 patents)

bronzeMedal Caroline Breitbach (3 out of 4 patents)

4.  Anne Moon (2 out of 2 patents)

5.  Tae-Ho Hwang (2 out of 2 patents)

Please report any incorrect information to support@idiyas.com
Loading…